BACKGROUND: Clinical studies suggest that inhaled corticosteroids reduce exacerbations and improve health status in @entity1030 ( @entity1030 ). However, their effect on mortality is unknown. METHODS: A pooled analysis, based on intention to treat, of individual @entity1 data from seven randomised trials (involving 5085 @entity1 ) was performed in which the effects of inhaled @entity288 and placebo were compared over at least 12 months in @entity1 with stable @entity1030 . The end point was all-cause mortality. RESULTS: Overall, 4% of the @entity1 died during a mean follow up period of 26 months. Inhaled corticosteroids reduced all-cause mortality by about 25% relative to placebo. Stratification by individual trials and adjustments for age, sex, baseline post-bronchodilator percentage predicted forced expiratory volume in 1 second, smoking status, and body mass index did not materially change the results (adjusted hazard ratio (HR) 0.73; 95% confidence interval (CI) 0.55 to 0.96). Although there was considerable overlap between subgroups in terms of effect sizes, the beneficial effect was especially noticeable in @entity1 (adjusted HR 0.46; 95% CI 0.24 to 0.91) and former smokers (adjusted HR 0.60; 95% CI 0.39 to 0.93). CONCLUSIONS: Inhaled corticosteroids reduce all-cause mortality in @entity1030 . Further studies are required to determine whether the survival benefits persist beyond 2-3 years.

Inhaled corticosteroids and mortality in XXXX .

@entity1 :: ('9606', 'Species') :: ['participants', 'women', 'patients', 'patient'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids'] @entity1030 :: ('MESH:D029424', 'Disease') :: ['chronic obstructive pulmonary disease', 'COPD']
@entity1030 :: (MESH:D029424,Disease) :: ['chronic obstructive pulmonary disease']
